Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IR quetiapine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| IR (Immediate-Release) quetiapine fumarate (drug) | DRUG | - |
Inclusion Criteria: * Men and women age ≥18 to ≤65 years with acute schizophrenia * Provision of written informed consent prior to enrolment Exclusion Criteria: * Meeting the criteria for any other (than schizophrenia) psychotic disorder not in full remission, concomitant organic mental disorder ...
IR quetiapine is an investigational small molecule being studied for the treatment of schizophrenia. It is an immediate-release formulation of quetiapine, a psychiatry medication. As of the available data, it is in Phase 2 clinical development and has not been approved by regulatory authorities.
IR quetiapine is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with schizophrenia.
IR quetiapine is currently in Phase 2 clinical development. It is an investigational drug, meaning it has not yet received regulatory approval for marketing. The drug is being studied for the treatment of schizophrenia, and its development is ongoing.
IR quetiapine has one completed clinical trial, identified by the National Clinical Trial number NCT00254787. This Phase 2 study, titled "Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients," enrolled 30 participants in Germany. The trial was randomized and double-blind, though it did not use a control group.
IR quetiapine is not FDA approved. It is an investigational drug currently in Phase 2 clinical trials for the treatment of schizophrenia. The drug has not completed the clinical development process required for regulatory approval, and its safety and efficacy have not been fully established.